AI-enabled Digital Pathology

Paige Prostate Detect* | CE-IVDR, FDA-AUTHORIZED

AI application that helps pathologists find possible cancer in digital images of prostate biopsy slides. Paige Prostate Detect should be used in combination with specific scanners and viewers, and should only be used to support, not replace, a pathologist’s full evaluation.

Assists in the detection of even minute foci on slides that are suspicious for cancer: offers high patient-level sensitivity and negative predictive value in cancer detection while decreasing pathologists’ reading times by 20%.^1,2

Paige Prostate Grade & Quantify** | CE-IVDR, RUO

Categorizes areas suspicious for cancer by Gleason pattern, providing predictions for primary and secondary Gleason grades. It also offers percentage and linear measurements of the tumor burden.

Paige Prostate Perineural Invasion (PNI)** | CE-IVDR, RUO

Aids in the detection of suspicious foci around nerve fibers to identify the presence of PNI.

Paige Breast Detect & Neoplasm^† | RUO

Highlights areas most likely to harbor cancer and in situ neoplasms, focusing your review on critical regions of the slide.

Paige Breast Mitosis^† | RUO

Identifies mitotic hotspots and provides a count and density of mitotic instances, allowing you to easily review individual mitotic figures to aid in grading.

Paige Breast Lymph Node^† | RUO
Detects foci suspicious for breast cancer in lymph node specimens: a study of anatomic pathologists demonstrated that use of Paige Breast Lymph Node improved pathologist sensitivity while cutting slide read times by over half.³

Paige PanCancer Detect^† | RUO
Detect suspicious tissue across more than 40 cancer types to support your research with pre-screening of all biopsy and resected tissue, or as a second review for quality control. Achieved 0.95 specimen-level AUC across nine common and seven rare cancers.⁴

Paige Breast Detect & Subtype^† | RUO

Paige GI Detect & Subtype^† | RUO

Paige GYN Detect & Subtype

Paige Bladder Detect & Subtype

Forecasts total nucleic acid (TNA) yield from an H&E image to identify samples at risk of NGS failure.

Accelerate biomarker screening across samples
Provides results in approximately 5 minutes to accelerate sample selection for testing across NGS, hotspot testing, IHC, and special stains.

Receive genomic insights across cancer types
Predictions can help researchers prioritize use of tissue, especially in cancers with often limited tissue (e.g., NSCLC) or less well tested indications (e.g., Melanoma, Endometrium).

Enrich cohorts for research at scale
Pre-screen samples for biomarkers of interest to help enable relevant sample identification at scale, supporting research and time to enrollment in clinical studies.

Tissue optimization
Tempus has integrated Paige Predict’s tissue optimization capabilities into our clinical laboratory workflow to help our pathologists conserve tissue and maximize the chances of a successful result. This process has reduced tissue utilization by 18% and is expected to lower the overall QNS rate by 15%.⁵

Biomarker prediction
Paige Predict’s biomarker predictions for 123 clinically relevant features across 16 cancer cohorts have been validated for clinical use as a Tempus laboratory developed test and is performed for eligible xT QNS cases, helping to inform confirmatory testing strategies.

Access Paige applications within your current digital pathology ecosystem, maintaining use of your preferred scanner, IMS, and viewer.

Use the Paige IMS, a secure, cloud-native platform that includes the FullFocus® Image Viewer^‡, FullFolio™ case management, and an application marketplace for third-party AI.

AI-native web viewer
FullFocus® provides high-performance visualization accessible from any authorized location.

Hardware agnostic
Seamlessly integrates with existing digital scanners, including Philips, Leica, and Hamamatsu.

Cloud-native scale
Flexible case management (FullFolio™) and storage designed for large-scale digital pathology without the need for on-premise hardware.